Suppr超能文献

生命链接基金会与坦帕的尸体肾移植

The LifeLink Foundation and cadaver kidney transplantation in Tampa.

作者信息

LeFor W M, Wright C E, Bowers V D, Heinrichs D F, Shires D L

机构信息

LifeLink Foundation, Inc., Tampa, Florida, USA.

出版信息

Clin Transpl. 1999:149-58.

Abstract
  1. LifeLink Foundation, a not-for-profit organization, has been the driving force and absolutely essential entity for kidney and liver transplantation in Tampa providing all the components (patient, organs and clinicians) save for inpatient hospitalization. It also plays a big role in the heart transplant program. LifeLink has increased the kidney transplant rate from the first 1,000 done in 17 years to the second 1,000 in 7 years and is on a pace for the third 1,000 in 5 1/2 years. 2. Because of its innovative programs, cadaver donor procurement by the Tampa LifeLink OPO has been roughly double the national average for the past 10 years. Because of cadaver kidney availability the median wait time from activation on the wait list to transplantation over the past 5 years was 159 days. The recent transplant rate is 14.7-22.7% higher than the national average, dependent upon the parameter measured. Similar results are seen for Tampa patients awaiting heart and liver transplantation. 3. The overall outcome of 1,184 cadaver kidney transplants performed in the decade 1989-98 was similar to that reported from the UNOS database in this series of publications. a) One- and 2-year graft survival increased 2% per year over the decade with a recent one-year graft survival rate of 96%. The overall T1/2 was 10 years. b) Our disastrous 1994 results were quickly reversed by a more intense pretransplant medical evaluation, the introduction of mycophenolate mofetil, more aggressive and earlier treatment of rejection episodes, and mandatory T- and B-cell flow cytometry crossmatching for all transplants. The incidence of rejection episodes decreased from 40 to 20%, and the first year immunological graft loss decreased from 5%, to 1.9%, to 0.8%, to 1.4% and 0% over the succeeding 4 years. 4. Individual factors affecting allograft survival were strikingly similar to national data, although all did not react statistical significance probably due to the smaller numbers. a) Primary and second grafts had similar survival rates (p = 0.97) whereas the third or subsequent graft survival was 7-32% poorer (p = 0.02). b) Black recipients had survival rates 10-13% lower than Caucasians and other races (p = 0.003). c) Patients with a peak PRA > 50 had survival values 4-13% poorer than those with < 50 PRA (p = 0.14). d) Patients with 2-4 HLA mismatches had graft survival rates 4-10% poorer than those with 0-1 mismatch (p = 0.12), whereas those with 5-6 mismatches had rates 6-17% poorer (p = 0.04). e) Although 22% of our transplants were to patients > 60 years of age, there was no difference (p = 0.81 to 0.90) in graft survival for the age groups 0-40, 41-60 and > 61. However, the proportion of grafts lost due to patient death compared with all allografts lost, was very different at 21% in the youngest group, 43% in those 41-60 years of age, and 63% in recipients > 61 years. 5. The rate of delayed graft function with imported kidneys was higher (27 vs. 16%, p = 0.006) but essentially the same as local kidneys with the same ischemia times. However, 41% of local kidneys were transplanted within 12 hours of procurement. Totally, 78% of local kidneys were transplanted within 18 hours (11% DGF rate) versus 79% of imports being transplanted at > 18 hours (32% DGF rate). Ischemia time, not the kidney source is the key issue since: a) There was no difference in overall graft survival of imported versus local kidneys (p = 0.95) nor in comparing local versus import kidneys with (p = 0.66) or without (p = 0.69) DGF. b) There was, however, a 11-17% overall poorer graft survival over 3 years in kidneys with DGF (p < 0.001) seen with both local (9-18% poorer, p = 0.0002) and imported (12-19% poorer, p = 0.008) kidneys. c) Kidneys displaying DGF came from older donors (40 vs. 34 years, p = 0.023) and had longer ischemia times (21 vs. 15 hours, p < 0.0005). 6. Dual kidney transplants were started in late 1996 with older or marginal donors to provide a better chance of success fo
摘要
  1. 生命链接基金会是一个非营利组织,一直是坦帕市肾脏和肝脏移植的推动力量及绝对重要的实体,它提供了除住院治疗之外的所有要素(患者、器官和临床医生)。它在心脏移植项目中也发挥着重要作用。生命链接基金会已将肾脏移植率从17年完成的首个1000例提高到7年完成的第二个1000例,并且正朝着在5年半内完成第三个1000例的目标迈进。

  2. 由于其创新项目,坦帕生命链接器官获取组织(OPO)在过去10年中尸体供体的获取量大致是全国平均水平的两倍。由于有尸体肾脏可用,过去5年从加入等待名单到移植的中位等待时间为159天。最近的移植率比全国平均水平高14.7 - 22.7%,具体取决于所测量的参数。等待心脏和肝脏移植的坦帕患者也有类似结果。

  3. 1989 - 1998年这十年间进行的1184例尸体肾脏移植的总体结果与该系列出版物中联合国器官共享网络(UNOS)数据库报告的结果相似。a) 在这十年中,1年和2年移植物存活率每年提高2%,最近的1年移植物存活率为96%。总体半衰期为10年。b) 1994年我们糟糕的结果通过更强化的移植前医学评估、霉酚酸酯的引入、对排斥反应更积极和更早的治疗以及所有移植都强制进行T细胞和B细胞流式细胞术交叉配型迅速得到扭转。排斥反应的发生率从40%降至20%,在随后的4年中,第一年免疫性移植物丢失率从5%降至1.9%,再降至0.8%,又降至1.4%,最后降至0%。

  4. 影响同种异体移植物存活的个体因素与全国数据惊人地相似,尽管可能由于数量较少,并非所有因素都具有统计学意义。a) 首次移植和再次移植的存活率相似(p = 0.97),而第三次或后续移植的存活率则低7 - 32%(p = 0.02)。b) 黑人受者的存活率比白人和其他种族低10 - 13%(p = 0.003)。c) 峰值群体反应性抗体(PRA)> 50的患者的存活率比PRA < 50的患者低4 - 13%(p = 0.14)。d) 有2 - 4个HLA错配的患者的移植物存活率比有0 - 1个错配的患者低4 - 10%(p = 0.12),而有5 - 6个错配的患者的存活率低6 - 17%(p = 0.04)。e) 尽管我们22%的移植是给60岁以上的患者,但0 - 40岁、41 - 60岁和> 61岁年龄组的移植物存活率没有差异(p = 0.81至0.90)。然而,因患者死亡导致的移植物丢失比例与所有同种异体移植物丢失相比,在最年轻组为21%,在41 - 60岁组为43%,在> 61岁的受者中为63%,差异很大。

  5. 进口肾脏的移植肾功能延迟发生率较高(27%对16%,p = 0.006),但在相同缺血时间下与本地肾脏基本相同。然而,41%的本地肾脏在获取后12小时内进行了移植。总体而言,78%的本地肾脏在18小时内进行了移植(移植肾功能延迟率为11%),而79%的进口肾脏在> 18小时进行了移植(移植肾功能延迟率为32%)。缺血时间而非肾脏来源是关键问题,因为:a) 进口肾脏与本地肾脏的总体移植物存活率没有差异(p = 0.95),在比较有(p = 0.66)或没有(p = 0.69)移植肾功能延迟的本地与进口肾脏时也没有差异。b) 然而,有移植肾功能延迟的肾脏在3年内总体移植物存活率比没有移植肾功能延迟的肾脏低11 - 17%(p < 0.001),本地肾脏(低9 - 18%,p = 0.0002)和进口肾脏(低12 - 19%,p = 0.008)均如此。c) 出现移植肾功能延迟的肾脏来自年龄较大的供者(40岁对34岁,p = 0.023),且缺血时间更长(21小时对15小时,p < 0.0005)。

  6. 1996年末开始进行双肾移植,供者为年龄较大或边缘供者,以提供更好的成功机会。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验